Synopsis
Psychedelics have been in the news a lot in 2024 because of the FDA’s consideration, and subsequent rejection, of MDMA as a therapeutic drug for people with PTSD. For DoSER’s 2024 December Dialogues, three experts discussed the wider context around psychedelics. As part of giving a fuller picture, they discussed: psychedelics’ long history in the use of sacred plants and medicines for Indigenous peoples; the legal and policy landscape for psychedelics; current work and research with psychedelics; and what may happen with FDA approval in the coming years.


